Last10K.com

Becton Dickinson Co (BDX) SEC Filing 10-Q Quarterly Report for the period ending Wednesday, March 31, 2021

Becton Dickinson Co

CIK: 10795 Ticker: BDX

Exhibit 99.1

1 Becton Drive
Franklin Lakes, NJ 07417
www.bd.com



bda181.jpg



Contact:
Investors: Kristen M. Stewart, CFA, SVP, Strategy & Investor Relations - 201-847-5378
Media: Troy Kirkpatrick, VP, Public Relations - 858-617-2361



BD ANNOUNCES SECOND FISCAL QUARTER RESULTS; REAFFIRMS FISCAL 2021 GUIDANCE

Second fiscal quarter revenues of $4.9 billion grew 15.4% on a reported basis. On a currency-neutral basis, revenues increased 12.2%.
BD’s COVID-19 testing sales were $480 million, including BD Veritor™ Plus System revenues of $290 million.
BD’s core growth led by strong growth in Medication Delivery Solutions (up 10.4%), Pharmaceutical Systems (up 15.4%), and Biosciences (up 16.3%) on a reported basis.
Second fiscal quarter GAAP diluted earnings per share (EPS) increased 77.4% year-over-year to $0.94.
Adjusted EPS increased 25.1% year-over-year to $3.19.
BD is reaffirming its fiscal 2021 revenue growth and adjusted EPS guidance.

Franklin Lakes, NJ (May 6, 2021)
- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.9 billion for the second fiscal quarter ended March 31, 2021. This represents an increase of 15.4% over the prior-year period on a reported basis and was driven by the contribution of BD’s COVID-19 diagnostic revenues, which totaled $480 million, as well as solid core business growth. On a currency-neutral basis, revenues increased 12.2%.

“We delivered strong revenue, earnings per share, and cash flow growth in the quarter and achieved several important milestones, most notably the recent submission of our 510(k) premarket notification for the BD Alaris™ System to the United States Food and Drug Administration,” said Tom Polen, Chairman, CEO and president of BD. “We also continued our essential role in the fight against COVID-19 by developing innovative diagnostic solutions and supplying the frontline with products urgently needed for patient care and vaccination —all while continuing to advance our growth and reinvestment initiatives. With our announced intention to spin off our diabetes business to shareholders, we are taking another bold step in our BD 2025 strategy, which focuses on unleashing our growth potential, delivering innovations for our customers, empowering our associates, and creating value for our shareholders.”

Second Fiscal Quarter 2021 Operating Results
As reported, diluted EPS for the second fiscal quarter were $0.94, compared with $0.53 in the prior-year period, which represents an increase of 77.4%. Adjusted diluted EPS were $3.19, compared with $2.55 in the prior-year period, which represents an increase of 25.1%, or 22.7% on a currency-neutral basis.





The following information was filed by Becton Dickinson Co (BDX) on Thursday, May 6, 2021 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Becton Dickinson Co's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Becton Dickinson Co.

Continue

Assess how Becton Dickinson Co's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Becton Dickinson Co's Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
Financial
Revenue
Legal
Other
Filter Subcategory:
All
Expense
Product
Income
Geography
Earnings
Shares
Other
Inside Becton Dickinson Co's 10-Q Quarterly Report:

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Cover Page
Condensed Consolidated Balance Sheets
Condensed Consolidated Statements Of Cash Flows
Condensed Consolidated Statements Of Comprehensive Income
Condensed Consolidated Statements Of Income
Accounting Changes
Accounting Changes (Policies)
Basis Of Presentation
Benefit Plans
Benefit Plans (Tables)
Benefit Plans - Net Pension And Postretirement Cost (Detail)
Business Restructuring Charges
Business Restructuring Charges (Tables)
Business Restructuring Charges - Summary Of Restructuring Accrual Activity (Detail)
Contingencies
Contingencies - Additional Information (Detail)
Debt
Debt - Additional Information (Detail)
Derivative Instruments And Hedging Activities
Derivative Instruments And Hedging Activities (Tables)
Derivative Instruments And Hedging Activities - Additional Information (Detail)
Derivative Instruments And Hedging Activities Disclosure - Gains (Losses) On Net Investment Hedges (Details)
Earnings Per Share
Earnings Per Share (Tables)
Earnings Per Share - Weighted Average Common Shares Used In Computations Of Basic And Diluted Earnings Per Share (Detail)
Financial Instruments And Fair Value Measurements
Financial Instruments And Fair Value Measurements (Tables)
Financial Instruments And Fair Value Measurements - Additional Information (Detail)
Financial Instruments And Fair Value Measurements - Cash And Equivalents And Restricted Cash (Details)
Intangible Assets
Intangible Assets (Tables)
Intangible Assets - Additional Information (Detail)
Intangible Assets - Components Of Intangible Assets (Detail)
Intangible Assets - Reconciliation Of Goodwill By Business Segment (Detail)
Revenues
Revenues - Additional Information (Details)
Segment Data
Segment Data (Tables)
Segment Data - Additional Information (Detail)
Segment Data - Financial Information For Company's Segments (Detail)
Segment Data - Revenues By Geographic Areas (Detail)
Shareholders' Equity
Shareholders' Equity (Tables)
Shareholders' Equity - Accumulated Other Comprehensive Income (Loss) - Components And Changes Of Accumulated Other Comprehensive Income (Loss) (Detail)
Shareholders' Equity - Changes In Certain Components Of Shareholders' Equity (Details)
Subsequent Events

Material Contracts, Statements, Certifications & more

Becton Dickinson Co provided additional information to their SEC Filing as exhibits

Ticker: BDX
CIK: 10795
Form Type: 10-Q Quarterly Report
Accession Number: 0000010795-21-000046
Submitted to the SEC: Thu May 06 2021 1:08:57 PM EST
Accepted by the SEC: Thu May 06 2021
Period: Wednesday, March 31, 2021
Industry: Surgical And Medical Instruments And Apparatus

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/bdx/0000010795-21-000046.htm